Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
Nehad M. Ayoub, Sara K. Jaradat, Kamal M. Al-Shami, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 267
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Seyedehdelaram Ghalehbandi, Jale Yüzügülen, Md Zahidul Islam Pranjol, et al.
European Journal of Pharmacology (2023) Vol. 949, pp. 175586-175586
Open Access | Times Cited: 132
Towards targeting the breast cancer immune microenvironment
Michael A. Harris, Peter Savas, Balaji Virassamy, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 554-577
Closed Access | Times Cited: 49
The complex role of MEG3: An emerging long non-coding RNA in breast cancer
Md Sadique Hussain, Abdullah A. Majami, Ali Haider, et al.
Pathology - Research and Practice (2023) Vol. 251, pp. 154850-154850
Closed Access | Times Cited: 46
Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers
Md Abdus Subhan, Nina Filipczak, Vladimir P. Torchilin
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 970-970
Open Access | Times Cited: 33
Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer
Klaudia Katarzyna Brogowska, Monika Zajkowska, Barbara Mroczko
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2412-2412
Open Access | Times Cited: 30
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Nityanand Srivastava, Salman Sadullah Usmani, Rajasekaran Subbarayan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 22
Cancer-associated fibroblast spatial heterogeneity and EMILIN1 expression in the tumor microenvironment modulate TGF-β activity and CD8+ T-cell infiltration in breast cancer
Chikako Honda, Sasagu Kurozumi, Takaaki Fujii, et al.
Theranostics (2024) Vol. 14, Iss. 5, pp. 1873-1885
Open Access | Times Cited: 13
The potential and promise for clinical application of adoptive T cell therapy in cancer
Yinqi Li, Yeteng Zheng, Taiqing Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Engineering chimeric antigen receptor T cells for solid tumour therapy
Longwei Liu, Yunjia Qu, Leonardo Cheng, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 29
Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies
Lenka Trnkova, Verona Buociková, Michal Mego, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116559-116559
Open Access | Times Cited: 7
Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies
Rasha M. Hassan, Islam H. Ali, Ahmed M. El Kerdawy, et al.
Bioorganic Chemistry (2024) Vol. 152, pp. 107728-107728
Closed Access | Times Cited: 7
Finding New Molecular Targets of Two Copper(II)-Hydrazone Complexes on Triple-Negative Breast Cancer Cells Using Mass-Spectrometry-Based Quantitative Proteomics
Lucía M. Balsa, María R. Rodríguez, Verónica Ferraresi-Curotto, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7531-7531
Open Access | Times Cited: 13
A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance
Guan–Jun Yang, Yanjun Liu, Lijian Ding, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Synergistic effects of sequential treatment with doxorubicin and zoledronic acid on anticancer effects in estrogen receptor-negative breast cancer cells
Apisara Danpipat, Kitiya Rujimongkon, Patthamapon Adchariyasakulchai, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
A review of the current status of biological effects of plant-derived therapeutics in breast cancer
Shantanu Pachal, Hitesh Kumar, Rupshee Jain, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Role of syndecan-4 in angiogenesis and vasculogenic mimicry in triple negative breast cancer cells
Jessica Oyie Sousa Onyeisi, Heba M. El‐Shorafa, Burkhard Greve, et al.
Matrix Biology (2025)
Open Access
Glyoxalase I Inhibitors Targeting Breast Cancer-Associated Endothelial Cells: An Integrated Network Pharmacology and Experimental Investigation
Honglin Jiang, Lu Yang, Qiuyue Sun, et al.
Journal of Molecular Structure (2025), pp. 141868-141868
Closed Access
The role of SOX18 in nasopharyngeal carcinoma: implications for prognosis and therapy
Gabris Ni, Wenbin Wang, Yuan Dang, et al.
American Journal of Translational Research (2025) Vol. 17, Iss. 2, pp. 913-926
Closed Access
LncRNAs in oncogenic microenvironment: from threat to therapy
Dipanjan Roy, B. Bhattacharya, Rudra Chakravarti, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access
SB218078 inhibits angiogenesis and epithelial-mesenchymal transition in breast cancer
Qianxue Wu, Jiawei Xu, Xin Tang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Optimizing ST6GAL1 inhibition and selectivity using lithocholic acid-amino acid conjugates for antimetastatic and antiangiogenic agent development
Wei‐Sheng Chen, Christian Angelo P. Concio, Tzu‐Ting Chang, et al.
Bioorganic Chemistry (2025), pp. 108401-108401
Closed Access
Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer
Xiaolu Sun, Kuai Liu, Shuli Lu, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5456-5456
Open Access | Times Cited: 16
Redefining the significance of quinoline containing compounds as potent VEGFR-2 inhibitors for cancer therapy
Jurnal Reang, Vinita Sharma, Vivek Yadav, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 7, pp. 1079-1099
Closed Access | Times Cited: 3
Neutrophils in pancreatic cancer: Potential therapeutic targets
Wenkai Jiang, Xin Li, Caifei Xiang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top